BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saubermann LJ, Deneau M, Falcone RA, Murray KF, Ali S, Kohli R, Ekong UD, Valentino PL, Grossman AB, Rand EB, Jonas MM, Saeed SA, Kamath BM. Hepatic Issues and Complications Associated With Inflammatory Bowel Disease: A Clinical Report From the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees. J Pediatr Gastroenterol Nutr 2017;64:639-52. [PMID: 27984347 DOI: 10.1097/MPG.0000000000001492] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Wasilewska A, Ponanta-gawron K, Burtan B, Stephen Chandra Sagaran C, Duplaga M, Kowalska-duplaga K. Exclusive Enteral Nutrition Remission Induction Treatment Influence on Transient Hypertransaminasemia in Children with Newly Onset Crohn's Disease. Journal of Medicinal Food. [DOI: 10.1089/jmf.2021.0069] [Reference Citation Analysis]
2 Cakir M, Sag E, Dogan G, Unal F, Kasirga E. Clinical significance of low transaminase levels in children with inflammatory bowel disease. World J Pediatr. 2019;15:143-147. [PMID: 30783951 DOI: 10.1007/s12519-019-00235-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Fousekis FS, Theopistos VI, Katsanos KH, Tsianos EV, Christodoulou DK. Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review. Gastroenterology Res. 2018;11:83-94. [PMID: 29707074 DOI: 10.14740/gr990w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
4 Kucharska M, Daniluk U, Kwiatek-Średzińska KA, Wasilewska N, Filimoniuk A, Jakimiec P, Zdanowicz K, Lebensztejn DM. Hepatobiliary manifestations of inflammatory bowel disease in children. Clin Exp Hepatol 2019;5:203-9. [PMID: 31598556 DOI: 10.5114/ceh.2019.87632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
5 Yaccob A, Mari A. Practical clinical approach to the evaluation of hepatobiliary disorders in inflammatory bowel disease. Frontline Gastroenterol 2019;10:309-15. [PMID: 31281626 DOI: 10.1136/flgastro-2018-101037] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
6 Nassar R, Waisbourd‐zinman O. Autoimmune liver disease in gastrointestinal conditions. Clinical Liver Disease. [DOI: 10.1002/cld.1223] [Reference Citation Analysis]
7 Polychronopoulou E, Lygoura V, Gatselis NK, Dalekos GN. Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis: consider primary biliary cholangitis not always primary sclerosing cholangitis. BMJ Case Rep. 2017;2017. [PMID: 28951510 DOI: 10.1136/bcr-2017-220824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Patel P, Dalal S. Hepatic Manifestations of Inflammatory Bowel Disease. Clin Liver Dis (Hoboken) 2021;17:292-6. [PMID: 33968391 DOI: 10.1002/cld.1046] [Reference Citation Analysis]